Followers | 368 |
Posts | 5333 |
Boards Moderated | 1 |
Alias Born | 05/09/2013 |
Wednesday, August 03, 2016 3:05:58 PM
LABD has been a flippable-day trade stock from Monday thru approx Tuesday (20-21's to 22-23's), but so far that's all it's proved. Still watching LABD for swing trade entry intent.
I was tempted the last couple days on LABD, but I'm still waiting to determine an entry point (for an intended daily chart swing trade).
An Important basic technical to keep in mind:
If the 20.50 (or 20+ approx) area holds on LABD yet past today thru this week yet, then it will likely be a good supportive sign for it and means market might be ready for an August correction lower.
Otherwise, in the mean time I'm not underestimating the bulls ability to resume uptrend a while yet on XBI(LABU) & stock market overall.
Recent ENLV News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/24/2024 12:33:16 PM
- Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis • GlobeNewswire Inc. • 09/24/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/11/2024 12:30:22 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/30/2024 08:30:38 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/23/2024 12:02:02 PM
- Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis • GlobeNewswire Inc. • 07/23/2024 12:00:00 PM
- Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis • GlobeNewswire Inc. • 06/24/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/20/2024 12:04:56 PM
- Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25 • GlobeNewswire Inc. • 06/20/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/17/2024 12:03:18 PM
- Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis • GlobeNewswire Inc. • 06/17/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/14/2024 08:30:24 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/03/2024 12:05:31 PM
- Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/29/2024 08:20:04 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/29/2024 08:15:50 PM
- Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering • GlobeNewswire Inc. • 05/29/2024 08:15:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/28/2024 12:13:35 PM
- Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering • GlobeNewswire Inc. • 05/28/2024 12:12:00 PM
- Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis • GlobeNewswire Inc. • 04/22/2024 12:00:00 PM
- Yet Another Biotech Stock Has Found Success During Tuesday's Session • AllPennyStocks.com • 04/16/2024 08:55:00 PM
- Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis • GlobeNewswire Inc. • 04/16/2024 11:50:00 AM
- Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis • GlobeNewswire Inc. • 04/11/2024 06:58:20 PM
- Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis • GlobeNewswire Inc. • 04/11/2024 12:05:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM